Regeneron's valuation gap anchors H2 biotech trade
Regeneron's strong first-quarter earnings have failed to close an 11% year-to-date share price decline, creating a low-beta entry point into a biotech sector poised for multiple regulatory catalysts in the second half of 2026.
Regeneron Pharmaceuticals is trading at $687.40, down 11.45% year to date as of July 28, despite posting first-quarter revenue of $3.605 billion that beat estimates by 3.5%. This disconnect between robust operational performance and a lagging share price is drawing attention from market professionals building risk-on positions in biotechnology for the back half of 2026.
The large-cap drugmaker reported 19.04% year-over-year revenue growth, driven primarily by its flagship immunology drug, Dupixent. Dupixent generated $4.88 billion in global first-quarter sales, a 33% increase serving over 1.4 million active patients. Meanwhile, Libtayo grew 54% and EYLEA HD U.S. sales jumped 77%.
Non-GAAP earnings per share of $9.47 easily cleared the $8.90 consensus estimate, while the balance sheet holds $18.54 billion in cash. Supported by $848 million in first-quarter free cash flow, management authorized a $3.0 billion share repurchase program in April alongside a $0.94 quarterly dividend. These capital returns provide a structural floor for a stock carrying a beta of just 0.236.
The clinical pipeline offers multiple near-term catalysts to close the current valuation gap. Regulatory decisions for garetosmab are expected in August 2026, with a cemdisiran NDA decision following in the fourth quarter. Fianlimab data in metastatic melanoma adds another potential positive inflection point for the stock.
However, the discounted valuation reflects legitimate commercial headwinds that investors must weigh. Legacy EYLEA U.S. sales fell 40% in the first quarter, and a Samsung Bioepis biosimilar is cleared to launch in January 2027. Furthermore, GAAP gross margins have narrowed to 77-78% due to an ongoing manufacturing disruption at a facility in Limerick, Ireland.
Despite these risks, the analyst consensus target sits at $833.31, with a base-case one-year model target of $888.57 implying 32.08% upside. The Street maintains 72% bullish sentiment with zero sell ratings. This large-cap stability anchors a broader biotech sector heading into a dense period of FDA action dates and Phase 3 obesity readouts.
Higher up the risk curve, the sector's dispersion allows for more aggressive positioning. Moderna has surged 177% ahead of an August 5 FDA flu vaccine ruling. Meanwhile, pre-revenue Viking Therapeutics sits near a 52-week high, carrying 175% analyst upside potential ahead of binary Phase 3 obesity trial data for its dual GLP-1/GIP treatment.
